Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Fallopian Tube Neoplasms 4Ovarian Neoplasms 3Triple Negative Breast Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Breast Neoplasms 2Uterine Cervical Neoplasms 1Solitary Fibrous Tumor, Pleural 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Neoplasm Metastasis 1Mesothelioma, Malignant 1Melanoma 1Leiomyosarcoma 1Glioblastoma 1Fallopian Tube Mucinous Adenocarcinoma 1Colorectal Neoplasms 1Carcinosarcoma 1Carcinoma, Endometrioid 1

Interventions

enzalutamide 33Abiraterone Acetate 29apalutamide 26Prednisone 26Radiotherapy 25Magnetic Resonance Spectroscopy 25Androgen Antagonists 24Leuprolide 22Radiosurgery 19darolutamide 18Docetaxel 17Gonadotropin-Releasing Hormone 16acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 15Goserelin 13gallium 68 PSMA-11 12bicalutamide 12Specimen Handling 12Radiotherapy, Intensity-Modulated 12abiraterone 11Radiation 11pembrolizumab 10Pluvicto 10Carboplatin 9Brachytherapy 92-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 9relugolix 8luprolide acetate gel depot 8Triptorelin Pamoate 8Standard of Care 8Nivolumab 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Prostatic Neoplasms × cediranib × Clear all
NCT02893917 2026-04-13

Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Olaparib) for Men With Advanced Prostate Cancer

National Cancer Institute (NCI)

Phase 2 Active not recruiting
90 enrolled 19 charts
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡